Compare Boston Scientific Corporation (BSX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Western Alliance Bancorporation — how do they compare? Boston Scientific Corporation trades at $42.71 (market cap $66.37B), while Western Alliance Bancorporation trades at $80.41 (market cap $8.77B). The key difference: Boston Scientific Corporation is far larger — about 7.6× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.09% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | WAL | |
|---|---|---|
Market Cap | $66.37B | $8.77B |
Sector | Health | Financials |
52-Week High | $108.14 | $96.08 |
52-Week Low | $42.63 | $66.70 |
Enterprise Value | $75.94B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Western Alliance Bancorporation (WAL) trades at $80.49, down 0.25% on the day, with a bearish technical signal and mixed fundamentals. The stock shows strong analyst support with a consensus price target of $90.67 and 79% buy ratings, but recent earnings beats are overshadowed by negative operating cash flow and high interest expenses. Recent news highlights strategic lending growth and industry recognition, including a #1 bank ranking in Arizona by Forbes in June 2026.
The outlook is cautiously optimistic given Wall Street's bullish stance and valuation discounts, but risks include cash flow pressures and macroeconomic sensitivity. Upside hinges on execution of lending growth and margin improvement, while downside could stem from credit quality deterioration or rising rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
